BLOG / 🇮🇳 India / index intelligence · · daily

BSE FMCG Sector Regulatory Filings — November 06, 2026

India BSE FMCG

By Gunpowder Editorial ·

2 high priority 10 medium priority 12 total filings analysed

Executive Summary

The November 6, 2026 BSE FMCG filings reveal a sector grappling with divergent growth trajectories and margin pressures.

Marico stands out with Q2FY27 revenue growth of 13%, EBITDA up 27%, and PAT up 31%—the highest profit growth in 50 quarters—driven by a 600 bps gross margin expansion and 10% India volume growth, despite a high single-digit decline in Saffola Edible Oil volumes due to deliberate rationalization. Britannia reported Q2FY27 revenue growth of 16.6% YoY but operating profit grew only 8.5%, with H1 FY27 operating margin at 16.2% versus 17.0% in FY25-26, signaling input cost pressures from palm oil, flour, and fuel. Emami's Q2FY27 consolidated revenue rose 15.4% YoY, but net profit plunged 95.8% due to a prior-year exceptional item, while standalone net profit fell 27.1%. Dabur faced a SEBI administrative warning for delayed disclosure of a USFDA warning letter, highlighting regulatory compliance risks. Marico also announced two strategic acquisitions—increasing its stake in Cosmix Wellness to 80% for Rs. 113.65 Crore and acquiring 51% of Bonorizon for up to Rs. 35 Crore—to accelerate digital and international growth. Overall, the sector shows a mix of strong operational performance from Marico, margin challenges at Britannia, and regulatory headwinds for Dabur, with capital allocation favoring strategic M&A over shareholder returns in the near term.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance · M&A

Tracking the trend? Catch up on the prior BSE FMCG Sector Regulatory Filings digest from November 05, 2026.

Investment Signals (12)

  • Marico ↓ (BULLISH)
    ▲

    Q2FY27 revenue +13% YoY, EBITDA +27%, PAT +31% (highest in 50 quarters), gross margin +600 bps, EBITDA margin +200 bps to 18.2%

  • Marico ↓ (BULLISH)
    ▲

    India volume growth 10% YoY, international constant currency growth 13%, A&P spend +44% YoY, demonstrating strong brand investment

  • Marico ↓ (BULLISH)
    ▲

    Acquired additional 20% stake in Cosmix Wellness for Rs. 113.65 Crore; Cosmix turnover grew from Rs. 24.32 Crore (FY24) to Rs. 91.53 Crore (FY26), ARR >Rs. 170 Crore

  • Marico ↓ (BULLISH)
    ▲

    Acquired 51% of Bonorizon for up to Rs. 35 Crore to accelerate digital growth in international markets

  • Britannia ↓ (BULLISH)
    ▲

    Q2FY27 revenue +16.6% YoY, +11.6% QoQ; operating margin recovered to 17.0% from 15.3% in Q1FY27

  • Britannia ↓ (BULLISH)
    ▲

    H1FY27 revenue +13.1% YoY, PAT +11.7% YoY, indicating resilient demand

  • Emami ↓ (BULLISH)
    ▲

    Q2FY27 consolidated revenue +15.4% YoY to Rs. 9,643.31 million, showing strong top-line growth

  • Emami ↓ (BULLISH)
    ▲

    Completed 1:10 stock split effective October 22, 2026, improving liquidity and retail participation

  • Dabur ↓ (NEUTRAL)
    ▲

    SEBI warning for delayed disclosure is administrative, no financial or operational impact stated; company to place before board

  • Marico ↓ (NEUTRAL)
    ▲

    Appointed Rohit Jawa as Independent Director for 5-year term from Jan 1, 2027, strengthening board governance

  • Britannia ↓ (BEARISH)
    ▲

    Input costs rose sharply QoQ (refined palm oil +11%, flour +9%, milk +7%, laminate +45% YoY), posing margin risk

  • Emami ↓ (BEARISH)
    ▲

    Standalone net profit fell 27.1% YoY to Rs. 712.26 million; PBT down 9.2% YoY, indicating profitability pressure

Risk Flags (10)

  • Britannia↓ [HIGH RISK]
    ▼

    H1FY27 operating margin 16.2% vs 17.0% in FY25-26; PAT margin fell to 12.5% from 13.4%; input costs rising (palm oil +11% QoQ, flour +9% QoQ, laminate +45% YoY)

  • Dabur↓ [HIGH RISK]
    ▼

    SEBI administrative warning for delayed disclosure of USFDA warning letter received July 24, 2026; warns of stricter action for future lapses; reputational and compliance risk

  • Emami↓ [HIGH RISK]
    ▼

    Consolidated net profit plunged 95.8% YoY to Rs. 714.18 million due to prior-year exceptional item; standalone net profit down 27.1% YoY; PBT down 9.2% YoY

  • Marico↓ [MEDIUM RISK]
    ▼

    Saffola Edible Oil volume declined high single-digit due to rationalization; process to complete over next 2-3 quarters, impacting near-term revenue

  • Marico↓ [MEDIUM RISK]
    ▼

    Bangladesh grew only 5% in constant currency amid persistent inflation and macroeconomic challenges, though 2-year CAGR is 13%

  • Britannia↓ [MEDIUM RISK]
    ▼

    Operating profit grew only 8.5% YoY vs revenue growth of 16.6%, indicating inability to fully pass on costs

  • Marico↓ [MEDIUM RISK]
    ▼

    A&P spend rose 44% YoY; A&P to sales ratio expected at ~10-10.5% next year, which may pressure margins if growth slows

  • Dabur↓ [MEDIUM RISK]
    ▼

    USFDA warning letter (received July 24, 2026) underlying the SEBI warning; potential regulatory overhang on US operations

  • Emami↓ [LOW RISK]
    ▼

    H1FY27 standalone total income Rs. 36,325.00 million vs Q2 alone Rs. 9,643.31 million, implying Q1 was stronger; need to monitor quarterly volatility

  • Godrej Consumer↓ [LOW RISK]
    ▼

    Loss of share certificates for two shareholders (600 shares each) is routine but indicates administrative processes; no financial impact

Opportunities (10)

  • Marico↓ (OPPORTUNITY)
    ◆

    Strong Q2FY27 performance with highest profit growth in 50 quarters; gross margin expansion and volume growth could drive re-rating; watch for continued momentum

  • Marico↓ (OPPORTUNITY)
    ◆

    Cosmix Wellness acquisition at attractive valuation (Rs. 113.65 Crore for 20% implies ~Rs. 568 Crore valuation) with fast-growing digital wellness brand; potential for high growth

  • Marico↓ (OPPORTUNITY)
    ◆

    Bonorizon acquisition for digital international growth; small ticket size (Rs. 35 Crore) but strategic; right to acquire remaining stake after 3 years

  • Britannia↓ (OPPORTUNITY)
    ◆

    Q2FY27 operating margin recovery to 17.0% from 15.3% QoQ shows ability to manage costs; if input costs stabilize, margins could improve further

  • Britannia↓ (OPPORTUNITY)
    ◆

    Revenue growth of 16.6% YoY outpacing sector, indicating market share gains; H1FY27 revenue +13.1% YoY

  • Emami↓ (OPPORTUNITY)
    ◆

    Revenue growth of 15.4% YoY despite profit decline due to one-off; underlying business growth is strong; stock split may improve liquidity

  • Dabur↓ (OPPORTUNITY)
    ◆

    SEBI warning is administrative with no financial impact; stock may overreact, creating buying opportunity if fundamentals intact

  • Marico↓ (OPPORTUNITY)
    ◆

    Board strengthening with appointment of Rohit Jawa as Independent Director; brings valuable experience (ex-HUL)

  • Godrej Consumer↓ (NEUTRAL)
    ◆

    Routine compliance filing; no impact; focus on core business

  • Dabur↓ (NEUTRAL)
    ◆

    ESOP allotment of 1,07,691 shares (0.0006% of capital) is negligible; indicates employee confidence

Sector Themes (6)

  • Divergent Margin Trends
    ◆

    Marico expanded gross margin by 600 bps YoY and EBITDA margin by 200 bps, while Britannia's operating margin contracted 80 bps YoY in H1FY27 and Emami's profitability declined; input cost inflation (palm oil, flour) is impacting players differently based on portfolio mix and pricing power.

  • Strategic M&A for Digital Growth
    ◆

    Marico announced two acquisitions (Cosmix Wellness and Bonorizon) to accelerate digital and international growth, signaling a sector trend of FMCG companies acquiring digital-first brands to tap new channels and premium segments.

  • Regulatory Scrutiny Intensifies
    ◆

    Dabur received a SEBI warning for delayed disclosure of a USFDA warning letter, highlighting increased regulatory focus on timely disclosures; companies need robust compliance frameworks.

  • Volume Growth vs. Value Growth
    ◆

    Marico reported 10% India volume growth, while Britannia's revenue growth may be price-led; distinguishing volume and value growth is critical to assess underlying demand.

  • Capital Allocation Mix
    ◆

    Marico is prioritizing M&A (total ~Rs. 148.65 Crore) over dividends/buybacks, while Emami completed a stock split to enhance liquidity; sector sees a blend of growth investments and shareholder-friendly actions.

  • International Market Challenges
    ◆

    Marico's Bangladesh growth slowed to 5% in constant currency due to inflation, while international constant currency growth overall was 13%; geopolitical and macroeconomic factors are impacting emerging markets.

Watch List (8)

  • 👁

    Q2FY27 earnings call transcript to be released; watch for management commentary on Saffola rationalization progress and Bangladesh recovery; A&P to sales ratio guidance of ~10-10.5% for next year.

  • Investors/Analysts Conference Call held Nov 6, 2026; audio recording available; watch for margin outlook and input cost trends.

  • 👁

    SEBI warning to be placed before board; watch for corrective actions and potential USFDA developments; board meeting date not disclosed.

  • 👁

    Post stock split, watch for liquidity improvement and investor reaction; Q3FY27 results will clarify if profit decline was one-off.

  • 👁

    Cosmix Wellness and Bonorizon acquisitions completion within 90 days; watch for integration updates and milestone achievements.

  • 👁

    Postal ballot for Rohit Jawa's appointment as Independent Director; e-voting from Nov 8 to Dec 7, 2026; results by Dec 9, 2026.

  • Duplicate share certificates issuance for two shareholders; routine but monitor for any broader administrative issues.

  • 👁

    RTA office address change effective Dec 1, 2026; ensure smooth transition for shareholder services.

Filing Analyses (12)
Britannia Industries Limited Market Notice mixed materiality 7/10

06-11-2026

Britannia Industries reported Q2 FY27 consolidated revenue from operations of ₹5,542 Crore, up 16.6% YoY and 11.6% QoQ, with PAT (owner's share) at ₹721 Crore (+10.2% YoY, 13.0% of revenue). However, operating profit grew slower at 8.5% YoY to ₹943 Crore and operating margin stood at 17.0% versus 15.3% in Q1'27 but roughly flat versus 17.0% in FY25-26, while input costs rose sharply QoQ (refined palm oil +11%, flour +9%, industrial fuel +2%, milk +7%) and laminate jumped 45% YoY. H1 FY27 revenue was ₹10,506 Crore (+13.1% YoY) with PAT of ₹1,312 Crore (+11.7% YoY), though H1 operating margin of 16.2% was below the 17.0% FY25-26 level.

  • · Operating profit grew only 8.5% YoY in Q2 FY27 versus 16.6% revenue growth, indicating margin pressure
  • · H1 FY27 operating margin of 16.2% was below FY25-26's 17.0%, and PAT margin fell to 12.5% from 13.4%
  • · Q2 FY27 operating margin recovered to 17.0% from 15.3% in Q1 FY27
  • · Refined palm oil costs rose 17% YoY and 11% QoQ; laminate up 45% YoY; industrial fuel up 18% YoY
  • · Flour costs declined 4% YoY but rose 9% QoQ; laminate declined 21% QoQ
  • · General Trade growth in Q2 FY27 was 2.6x that of FY25-26; other channels grew at 1.8x GT; e-commerce now ~7% of revenue
  • · Key States (over 50% of domestic revenue) grew 2.8x FY25-26 rate, while Other States outpaced Key States
  • · Adjacent bakery businesses (cake, rusk, wafers, croissant) grew over 20% in the quarter; international business rebounded to mid-teens growth; dairy (cheese, ghee, milk drinks) grew double digits
  • · ESG: women 45% of factory workforce, renewable electricity 48% of own plants, 5,73,663 BNF beneficiaries in H1 FY27
  • · Revenue growth trajectory: FY23-24 4%, FY24-25 6%, FY25-26 8%, H1 FY27 13% (12-month growth basis)
  • · Presentation filed under Regulation 30 of SEBI Listing Regulations; audio recording and transcript to follow within prescribed timelines
Marico Limited Corporate Governance neutral materiality 4/10

06-11-2026

Marico Limited has issued a Postal Ballot Notice seeking shareholder approval via Special Resolution to appoint Mr. Rohit Jawa (DIN: 10063590) as an Independent Director for a 5-year term from January 1, 2027 to December 31, 2031. Remote e-voting runs from November 8, 2026 (9:00 a.m. IST) to December 7, 2026 (5:00 p.m. IST), with results to be declared on or before December 9, 2026. The filing contains no financial or operational performance data, so no period-over-period comparison is applicable.

  • · Cut-off date for e-voting eligibility: Friday, October 30, 2026
  • · Board meeting appointing Scrutinizer held on November 2, 2026
  • · Mr. Rohit Jawa appointed as Additional Director (Independent) by the Board effective January 1, 2027, subject to shareholder approval
  • · Appointment is not liable to retire by rotation
  • · Postal Ballot Notice sent only by electronic mode per MCA Circulars (General Circular No. 14/2020, 17/2020, and 3/2025 dated September 22, 2025)
  • · Resolution deemed passed on December 7, 2026 if approved by requisite majority
  • · Company CIN: L15140MH1988PLC049208; Scrip Code 531642; Scrip Symbol MARICO
Dabur India Limited Market Update neutral materiality 2/10

06-11-2026

Dabur India Limited allotted 1,07,691 equity shares of Rs. 1 each on November 06, 2026, following option exercises by employees of the Company and its subsidiaries under the Dabur Employees Stock Option Scheme 2000. The allotment raised paid-up equity share capital from Rs. 177,39,57,506 to Rs. 177,40,65,197, an increase of Rs. 1,07,691 (approximately 0.0006%). The new shares rank pari passu with existing equity shares, with no other financial or operational metrics disclosed.

  • · Allotment approved by the Nomination & Remuneration Committee on Friday, November 06, 2026
  • · Shares allotted pursuant to option exercise by employees of the Company and its subsidiaries
  • · New shares rank pari passu in all aspects with existing equity shares
  • · BSE Scrip Code: 500096; NSE Scrip Symbol: DABUR
  • · Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015
Marico Limited Analyst/Investor Meet positive materiality 8/10

06-11-2026

Marico reported Q2FY27 consolidated revenue growth of 13%, driven by 10% India volume growth and 13% constant currency international growth, with EBITDA up 27% and PAT up 31% — the highest profit growth in 50 quarters. Gross margin expanded ~600 bps YoY on favorable mix and softer copra, while A&P spend rose 44% and EBITDA margin expanded 200 bps to 18.2%. However, Saffola Edible Oil saw a high single-digit volume decline from deliberate rationalization of low-margin variants (revenue +6%), and Bangladesh grew only 5% in constant currency amid persistent inflation and demand softness.

  • · Saffola Edible Oil volume declined high single-digit due to deliberate rationalization of low-margin variants; process to complete over next 2-3 quarters
  • · Bangladesh grew only 5% in constant currency amid persistent inflation and macroeconomic challenges, though 2-year CAGR is 13%
  • · A&P to sales ratio expected at ~10% to 10.5% next year; A&P growth to normalize to double-digit in India
  • · FY27 EBITDA margin could expand by about 120 to 150 basis points
  • · FY28 EBITDA growth guidance maintained at least mid-teens
  • · Digital-first portfolio growth now normative at ~20-25%
  • · Growth portfolio now 27% of India business, up from 20% earlier
  • · Just Herbs still loss-making; breakeven expected over the next few quarters
  • · Copra prices rangebound about 35% below last year's peak, but crude-linked derivatives and vegetable oils rising
  • · FY29 revenue CAGR implied at about 13% to 14%
  • · Soya Chunks ARR near INR100 crores
  • · Parachute medium-term volume growth guidance of 4% to 6%
Emami Limited Market Update mixed materiality 6/10

06-11-2026

Emami Limited published its unaudited standalone and consolidated financial results for Q2/H1 FY27 (quarter ended September 30, 2026) in newspapers on November 6, 2026, following Board approval on November 5, 2026. Consolidated revenue rose 15.4% YoY to ₹9,643.31 million, but consolidated net profit plunged 95.8% YoY to ₹714.18 million (from ₹16,827.94 million), which included an exceptional prior-year item; standalone net profit fell 27.1% YoY to ₹712.26 million. The company also completed a 1:10 stock split, subdividing each ₹10 share into ten ₹1 shares effective October 22, 2026.

  • · Standalone total income: ₹9,643.31 million in Q2 FY27 vs ₹8,353.32 million in Q2 FY26 (up 15.4% YoY); H1 FY27 ₹36,325.00 million.
  • · Consolidated total income: ₹9,643.31 million in Q2 FY27 vs ₹8,353.32 million in Q2 FY26 (up 15.4% YoY); H1 FY27 ₹36,976.87 million.
  • · Standalone PBT: ₹887.43 million in Q2 FY27 vs ₹977.11 million in Q2 FY26 (down 9.2% YoY); H1 FY27 ₹4,534.00 million.
  • · Consolidated PBT: ₹888.43 million in Q2 FY27 vs ₹978.11 million in Q2 FY26 (down 9.2% YoY); H1 FY27 ₹5,196.00 million.
  • · Standalone net profit: ₹712.26 million in Q2 FY27 vs ₹16,826.69 million in Q2 FY26 (down 95.8% YoY); H1 FY27 ₹19,177.00 million.
  • · Consolidated net profit: ₹714.18 million in Q2 FY27 vs ₹16,827.94 million in Q2 FY26 (down 95.8% YoY); H1 FY27 ₹19,737.87 million.
  • · Standalone EPS: ₹15.63 in Q2 FY27 vs ₹369.50 in Q2 FY26; H1 FY27 ₹421.10.
  • · Consolidated EPS: ₹15.68 in Q2 FY27 vs ₹369.52 in Q2 FY26; H1 FY27 ₹433.42.
  • · Paid-up equity share capital: ₹455.40 million as of September 30, 2026, September 30, 2025, and March 31, 2026.
  • · Stock split: each ₹10 share subdivided into ten ₹1 shares; record date October 22, 2026.
  • · Results reviewed by Audit Committee on November 3, 2026 (standalone) and November 4, 2026 (consolidated), and approved by the Board on November 5, 2026.
  • · Results subject to limited review by statutory auditors.
  • · Published in Business Standard (English) and Aajkaal (Bengali) on November 6, 2026.
  • · Scrip codes: NSE EMAMILTD, BSE 531162.
Godrej Consumer Products Limited Market Update neutral materiality 1/10

06-11-2026

Godrej Consumer Products Limited published a newspaper advertisement (Financial Express, All India Edition, November 6, 2026) as a public notice regarding loss of share certificates and issuance of duplicate securities, disclosed under Regulation 30 of SEBI LODR and in compliance with SEBI Circular HO/38/13/11(3)2025-MIRSD-POD/I/1102/2025 dated December 24, 2025. The notice concerns two shareholders (Karuna Chandra, folio 0311917, 600 shares; and a second holder, folio 608543, 600 shares) who reported lost/misplaced certificates and requested duplicate securities. This is a routine administrative/compliance disclosure with no financial or operational impact on the company.

  • · Notice published in Financial Express (English) – All India Edition on November 6, 2026
  • · Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
  • · Compliance referenced to SEBI Circular No. HO/38/13/11(3)2025-MIRSD-POD/I/1102/2025 dated December 24, 2025
  • · Claimants must object within 15 days of publication; absent objection, duplicate securities will be issued in dematerialised form
  • · Registrar and Share Transfer Agent: MUFG Intime India Private Limited, C101, Embassy 247, L.B.S. Marg, Vikhroli West, Mumbai – 400083
  • · Company CIN: L24246MH2000PLC129806; BSE Scrip Code 532424; NSE Symbol GODREJCP
Britannia Industries Limited Analyst/Investor Meet neutral materiality 2/10

06-11-2026

Britannia Industries Limited disclosed the audio recording link for its Investors/Analysts Conference Call (Group Meet) held on Friday, 6 November 2026 at 9:00 A.M. IST, covering financial results and operations for the quarter and half year ended 30 September 2026. The filing is a routine Regulation 30 compliance intimation with no financial figures disclosed; the transcript will be shared with exchanges and hosted on the company website within prescribed timelines.

  • · Scrip Code: 500825; NSE Symbol: BRITANNIA
  • · Conference call held at 9:00 A.M. IST on Friday, 6 November 2026
  • · Results period covered: quarter and half year ended 30 September 2026
  • · Audio recording link: https://media.britannia.co.in/Analyst Call Recording Q2 FY 26-27
  • · Filing made under Regulation 30 read with Clause 15 of Para A of Part A of Schedule III of SEBI Listing Regulations, 2015
  • · Transcript to be disseminated to stock exchanges and hosted on company website within prescribed timelines
Dabur India Limited Market Update negative materiality 6/10

06-11-2026

SEBI issued an administrative warning letter to Dabur India on November 6, 2026, alleging violation of Regulation 30(6)(iii) of SEBI (LODR) Regulations due to a delay in disclosing a USFDA warning letter received on July 24, 2026. The company stated there is no impact on its financial or operational activities, but SEBI warned of stricter action for future lapses and advised placing the communication before the board.

  • · SEBI's warning letter is dated November 06, 2026, and was received via email at 12:40 p.m. on the same day.
  • · The alleged violation stems from a delay in disclosing a USFDA warning letter that Dabur received on July 24, 2026.
  • · SEBI advised the company to place the communication before its board of directors at the upcoming board meeting and forward their comments on corrective steps.
  • · SEBI warned that any repetition of such violation will be viewed seriously and may lead to enforcement action under the SEBI Act, 1992.
Britannia Industries Limited Market Update neutral materiality 2/10

06-11-2026

Britannia Industries Limited filed a market update on November 6, 2026, confirming that it published newspaper advertisements of its unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026, in Financial Express (English, all editions) and Sangbad Pratidin (Bengali, Kolkata edition). The disclosure was made under Regulation 30 and 47 of SEBI (LODR) Regulations, 2015, and was signed by Sona Rajora, Company Secretary and Compliance Officer. The filing itself contains no financial figures or performance data, so no period-over-period comparison is possible from this document.

  • · Scrip Code: 500825; NSE Symbol: BRITANNIA
  • · Results cover the quarter and half year ended 30 September 2026
  • · Advertisements published on 6 November 2026 in Financial Express (English – All editions) and Sangbad Pratidin (Bengali – Kolkata edition)
  • · Filing made under Regulation 30 and 47 of SEBI (LODR) Regulations, 2015
  • · Document digitally signed on 2026.11.06 at 15:43:44 +05'30'
  • · No financial figures, revenue, or profit numbers are disclosed in this filing
Marico Limited Merger/Acquisition positive materiality 7/10

06-11-2026

Marico Limited acquired an additional 20% stake in Cosmix Wellness Private Limited for Rs. 113.65 Crore, increasing its aggregate shareholding from 60% to 80%. Cosmix Wellness, a digital-first functional wellness brand, has shown strong turnover growth from Rs. 24.32 Crore in FY24 to Rs. 91.53 Crore in FY26, with a last 3-month ARR of Rs. 170+ Crore. However, the acquisition is a related party transaction on an arm's length basis, and Marico has the right to acquire the remaining stake after FY29 subject to milestones.

  • · Cosmix Wellness was incorporated on January 31, 2022, and is headquartered in Bengaluru.
  • · Marico has the right to acquire the remaining stake in Cosmix Wellness after completion of FY29, subject to achievement of certain milestones and requisite approvals.
  • · The acquisition is a related party transaction on an arm's length basis; the Promoter/Promoter Group of Marico do not have any interest in the transaction.
  • · No governmental or regulatory approvals are required for the acquisition.
  • · The acquisition was completed on November 6, 2026, with cash consideration.
Dabur India Limited Market Update neutral materiality 1/10

06-11-2026

Dabur India Limited informed BSE and NSE that the corporate office of its Registrar to an Issue and Share Transfer Agent (RTA), KFin Technologies Limited, will shift to a new address in Kokapet, Hyderabad effective December 01, 2026. The disclosure was made under the SEBI Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 06, 2026. The filing contains no financial or operational data and is purely administrative in nature.

  • · New RTA corporate office address effective December 1, 2026: KFin Technologies Limited, 6th Floor, South Tower, Rajapushpa West Avenue, Survey No. 115, Kokapet, Serilingampally Mandal, District - Ranga Reddy, Hyderabad-500075, Telangana
  • · Present RTA address: KFin Technologies Limited, Selenium Tower B, Plot 31 & 32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad - 500 032, Telangana
  • · BSE Scrip Code: 500096; NSE Scrip Symbol: DABUR
  • · Filing reference number: SEC/SE/2026-27
  • · SEBI Master Circular reference: HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 06, 2026
  • · Dabur CIN: L24230DL1975PLC007908; Registered Office: 8/3, Asaf Ali Road, New Delhi – 110 002
Marico Limited Merger/Acquisition positive materiality 6/10

06-11-2026

Marico Limited has entered into definitive agreements to acquire 51% of Bonorizon Consumer Ventures Private Limited for an aggregate cash consideration of up to Rs. 35 Crore, with completion expected within 90 days. The acquisition aligns with Marico's strategy to accelerate digital growth in international markets. Additionally, Marico has the right to acquire the remaining equity after 3 years, subject to milestones and approvals.

  • · The acquisition does not fall within related party transaction and promoter/promoter group have no interest.
  • · No governmental or regulatory approvals required for the acquisition.
  • · Bonorizon was incorporated on October 22, 2026, and is headquartered in Mumbai, India; turnover: Not Applicable.
  • · Marico has the right to acquire the remaining equity share capital and voting rights in Bonorizon after completion of 3 years from the date of signing definitive agreements, at a consideration to be determined at such time, subject to achievement of certain milestones, requisite approvals and terms and conditions under the definitive agreements.
  • · The transaction is expected to be completed within 90 days from the date of signing definitive agreements, subject to customary closing conditions.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 12 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE FMCG Sector Regulatory Filings

🇮🇳 More from India

View all →